ABITREXATE
 |
|
|
Package(a):
VIALS: 5 x 50 mg/2ml.
Dosage(a):
Initially: 10 mg/week I.M. or I.V. May increase to 25 mg/week for 6-13 weeks. Please refer to the manufacturer for further details.
Prescribing Restrictions:
Package(b):
VIALS: 1 x 500 mg/20 ml.
Dosage(b):
Initially: 10 mg/week I.M. or I.V. May increase to 25 mg/week for 6-13 weeks. Please refer to the manufacturer for further details.
Prescribing Restrictions:
Package(c):
VIALS: 1 x 1 G/10 ml.
Dosage(c):
Initially: 10 mg/week I.M. or I.V. May increase to 25 mg/week for 6-13 weeks. Please refer to the manufacturer for further details.
Prescribing Restrictions:
Package(d):
VIALS: 1 x 5 G/50 ml.
Dosage(d):
Initially: 10 mg/week I.M. or I.V. May increase to 25 mg/week for 6-13 weeks. Please refer to the manufacturer for further details.
Prescribing Restrictions:
Indications:
Antineoplastic chemotherapy: Treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. Palliation of acute lymphocytic leukemia. Treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. May be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Effective in the treatment of the advanced stages (III and IV Peter's Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides.
Psoriasis: because of the high risk attending its use, treatment is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation.
Rheumatoid arthritis: Can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose NSAIDs and usually a trial of at least one or more disease-modifying antirheumatic drugs.
Contra-Indications:
Hypersensitivity, psoriatic patients with severe renal or hepatic disorders, pre-existing blood dyscrasias, pregnant psoriatic patients.
Special Precautions:
Patients with malignant disease who have pre-existing bone marrow aplasia, leukopenia, thrombocytopenia, or anemia. Not suitable for intrathecal administration. Presence of infection, peptic ulcer, ulcerative colitis, debility and in neonates, infants and the elderly.
Side Effects:
Ulcerative stomatitis, leukopenia, nausea and abdominal distress, malaise, fatigue, chills, fever, dizziness and decreased resistance to infection, rashes, pruritus, urticaria, photosensitivity, depigmentation, alopecia, ecchymosis, telangiectasia, acne and furunculosis, bone marrow depression, leukopenia, thrombocytopenia, anemia, hypogammaglobulinemia, hemorrhage and septicemia, anorexia, vomiting, diarrhea, hematemesis, melena, gastrointestinal ulceration and bleeding, enteritis, hepatic toxicity, renal failure, azotemia, cystitis, hematuria, severe nephropathy, defective oogenesis or spermatogenesis, menstrual dysfunction, infertility, abortion and fetal defects, interstitial pneumonitis and chronic interstitial obstructive pulmonary disease, CNS toxicity. See prescribing information for further adverse reactions.
Drug Interactions:
Please contact distributing company for full details.
